Qyuns Therapeutics

company

About

Qyuns Therapeutics develops monoclonal antibody drugs for autoimmune diseases.

  • 51 - 100

Details

Last Funding Type
Series C
Last Funding Money Raised
¥100M
Industries
Health Care,Therapeutics
Founded date
Jan 1, 2015
Number Of Employee
51 - 100
Operating Status
Active

Qyuns is developing six candidates, most of them interleukin antibodies. It has two biosimilar drugs in China clinical trials, including a biosimilar to tocilizumab, a Chugai drug marketed as Actemra for various rheumatoid arthritis conditions.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
¥100M $20M
Qyuns Therapeutics has raised a total of ¥100M $20M in funding over 2 rounds. Their latest funding was raised on Mar 7, 2022 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 7, 2022 Series C ¥100M 1 Detail
May 7, 2020 Series B 1 Detail
Jul 31, 2019 Series B $20M 1 Detail

Investors

Number of Lead Investors
Number of Investors
3
Qyuns Therapeutics is funded by 3 investors. Shenzhen Kaiding Juncan venture Cci Capital and Jiayin Investment are the most recent investors.
Investor Name Lead Investor Funding Round
Shenzhen Kaiding Juncan venture Cci Capital Series C
Jiayin Investment Series B
Hefu Ruitai Series B